ANTIFUNGAL ACTIVITY OF A NEW TRIAZOLE, D0870, COMPARED WITH 4 OTHER ANTIFUNGAL AGENTS TESTED AGAINST CLINICAL ISOLATES OF CANDIDA-GLABRATA AND TORULOPSIS-GLABRATA

D0870 is a new triazole agent with potent, broad-spectrum antifungal a ctivity. We investigated the in vitro activity of D0870, fluconazole, itraconazole, amphotericin B, and 5-fluorocytosine (5FC) against 319 c linical isolates of Candida spp. and Torulopsis glabrata. In vitro sus ceptibility testing was performed using a microdilution broth method p erformed according to NCCLS guidelines. D0870 was very active (MIC(90) of 0.12 mu g/ml and 0.5 mu g/ml at 24 and 48 h incubation, respective ly) against all of the yeast isolates. D0870 was 2- to 32-foId more ac tive than amphotericin B and 2- to 8500-fold more active than 5FC. By comparison with the other triazoles, D0870 was generally 2- to 16-fold more active than itraconazole and greater than or equal to 16-fold mo re active than fluconazole. More than half (53%) of c. albicans isolat es with elevated fluconazole and itraconazole MICs (greater than or eq ual to 128 mu g/ml and >8.0 mu g/ml, respectively) were inhibited by l ess than or equal to 1.0 mu g/ml of D0870. Based on these studies, D08 70 has promising antifungal activity and warrants further in vitro and in viva investigation.